What is the recommended starting and maximum dose of trazodone for treating insomnia?

Trazodone Dosing for Insomnia

For insomnia, trazodone is explicitly NOT recommended as first-line or even second-line therapy; when used off-label despite guideline recommendations against it, the typical starting dose is 25–50 mg at bedtime, with a maximum of 100–150 mg for sleep (far below the FDA-approved antidepressant dosing of 150–600 mg daily). 1, 2

Guideline Position: Trazodone Should NOT Be Used for Primary Insomnia

The American Academy of Sleep Medicine and the Department of Veterans Affairs/Department of Defense explicitly recommend AGAINST using trazodone for chronic insomnia disorder. 1, 3 This recommendation is based on:

• No objective sleep benefit: Systematic reviews found no significant differences between trazodone (50–150 mg) and placebo for sleep efficiency, sleep onset latency, total sleep time, or wake after sleep onset 1, 3
• Modest subjective improvement only: While patients reported slightly better subjective sleep quality, this benefit was judged insufficient to outweigh safety concerns 1
• Adverse effects outweigh benefits: The guideline panels concluded that trazodone's side effect profile (daytime drowsiness, dizziness, orthostatic hypotension, psychomotor impairment) exceeds its minimal efficacy 1, 3
• Low-quality evidence: The supporting trials were very short (mean 1.7 weeks), with follow-up of only 1–4 weeks 1

Off-Label Dosing When Used Despite Recommendations

When clinicians choose to use trazodone off-label for insomnia (acknowledging this contradicts current guidelines):

Starting Dose

• 25–50 mg taken at bedtime 1, 4, 5
• Administer at least 1 hour before bedtime on an empty stomach to maximize effectiveness 1

Dose Titration

• If 25–50 mg is insufficient, increase to 75–100 mg 4, 6
• The effective dose range for 70% of patients in one PTSD-insomnia study was 50–200 mg nightly 7

Maximum Dose for Insomnia

• 100–150 mg at bedtime is the typical upper limit for sleep purposes 1, 7, 4, 8
• Doses above 150 mg approach antidepressant dosing and are inappropriate for isolated insomnia 1

Critical Distinction from Antidepressant Dosing

• The FDA-approved antidepressant starting dose is 150 mg/day in divided doses, with a maximum of 400 mg/day for outpatients and 600 mg/day for inpatients 2
• A 50 mg bedtime dose is insufficient for treating comorbid depression; full antidepressant dosing (150–300 mg) is required for mood treatment 1

Recommended Treatment Algorithm (Evidence-Based)

First-Line: Cognitive Behavioral Therapy for Insomnia (CBT-I)

• CBT-I must be offered before any medication 1, 3
• Components include sleep restriction therapy, stimulus control, and relaxation techniques 1
• Superior long-term efficacy with sustained benefits after discontinuation 1

Second-Line: FDA-Approved Hypnotics (When CBT-I Insufficient)

For sleep onset AND maintenance insomnia:

• Eszopiclone 2–3 mg (reduce to 1 mg in older adults) 1
• Zolpidem 10 mg (reduce to 5 mg in older adults) 1
• Temazepam 15–30 mg (reduce to 7.5 mg in older adults) 1

For sleep onset ONLY:

• Zaleplon 10 mg (reduce to 5 mg in older adults) 1
• Ramelteon 8 mg (preferred when substance-use history exists; no addiction potential) 1

For sleep maintenance ONLY:

• Low-dose doxepin 3–6 mg (most effective for maintenance, minimal side effects, no abuse potential) 1, 3
• Suvorexant 1

Third-Line: Trazodone (Only After First and Second-Line Failures)

• Trazodone is relegated to third-line status and should only be considered when FDA-approved hypnotics and CBT-I have failed 1
• More appropriate when comorbid depression or anxiety is present (though 50 mg is inadequate for treating major depression) 1

Critical Safety Warnings

Priapism (Medical Emergency)

• 12% incidence reported in one PTSD study (far higher than expected) 7
• Any prolonged, painful erection lasting >4 hours requires immediate emergency care 1
• Clinicians must directly ask male patients about this side effect 7

Respiratory Concerns

• Use with extreme caution in patients with compromised respiratory function (asthma, COPD, sleep apnea) 1, 3
• Avoid in patients with hepatic impairment or heart failure 1

Orthostatic Hypotension and Falls

• Dizziness and orthostatic hypotension are common, especially in older adults 1
• Instruct patients to rise slowly from seated or supine positions 1
• Consider dose reduction in elderly patients 1

Drug Interactions

• Avoid alcohol and other CNS depressants due to additive sedative effects 1
• Black box warning for combining with opioids (e.g., hydrocodone): risk of respiratory depression and death 1
• Monitor for additive sedation when combined with benzodiazepines 1

Complex Sleep Behaviors

• Counsel patients about risk of sleepwalking, sleep-driving, and other complex behaviors 1
• Allow a sleep window of 7–8 hours to reduce residual sedation 1

Pregnancy and Lactation

• Avoid in pregnancy and nursing 1
• Trazodone transfers into human milk 2

Alcohol Use Disorder

• Emerging evidence suggests trazodone may worsen drinking behavior in patients with alcohol use disorder 9
• Its metabolite meta-chlorophenylpiperazine induces increased alcohol craving and use 9

Common Pitfalls to Avoid

1. Using trazodone as first-line therapy for primary insomnia – contradicts current guidelines 1, 3
2. Prescribing trazodone without attempting CBT-I or FDA-approved hypnotics first 1
3. Assuming 50 mg will treat comorbid depression – antidepressant dosing requires 150–300 mg 1
4. Combining two sedating antidepressants 1
5. Failing to directly ask male patients about priapism 7
6. Using in patients with COPD or respiratory compromise without careful risk-benefit assessment 3
7. Prescribing without regular follow-up to assess effectiveness, side effects, and ongoing need 1

Medications to Avoid for Primary Insomnia

• Benzodiazepines (lorazepam, clonazepam) – higher dependency risk, falls, cognitive impairment 1
• Antihistamines (diphenhydramine) – lack efficacy data, anticholinergic burden, tolerance develops within 3–4 days 1
• Antipsychotics (quetiapine, olanzapine) – insufficient evidence, significant metabolic side effects 1
• Barbiturates and chloral hydrate 1

Recent Meta-Analytic Evidence (2024–2025)

A 2024 meta-analysis of 44 RCTs (3,935 participants) found that trazodone did NOT significantly impact subjective total sleep time (0.73 minutes, p=0.96) but did improve sleep quality (SMD=-0.58, p<0.01) and objective polysomnographic total sleep time (27.98 minutes, p=0.02) 10. However, trazodone was associated with significantly more dropouts due to adverse effects (RR=2.30, p<0.01) and more adverse effects overall (RR=1.18, p=0.02) 10.

A 2025 meta-analysis in depressive patients confirmed trazodone improved sleep quality (SMD=-0.827, p=0.001) and depression severity (SMD=-0.365, p<0.001), but adverse effects were more frequent, including blurred vision (OR=17.50), somnolence (OR=7.34), and sedation (OR=6.53) 11.

Monitoring and Follow-Up

When trazodone is used despite guideline recommendations:

• Assess effectiveness and adverse effects every few weeks initially 1
• Employ the lowest effective maintenance dose 1
• Taper medication when conditions allow rather than abrupt discontinuation 1, 2
• Reassess the ongoing need for pharmacotherapy regularly 1